Format

Send to

Choose Destination
Oncotarget. 2015 Dec 8;6(39):41566-81. doi: 10.18632/oncotarget.5893.

The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value.

Cohen PA1,2,3, Donini CF1,2,3, Nguyen NT1,2,3, Lincet H1,2,3, Vendrell JA1,2,3.

Author information

1
ISPB, Faculté de Pharmacie, Lyon, France.
2
Université Lyon 1, Lyon, France.
3
INSERM U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.

Abstract

The recently described oncogene ZNF217 belongs to a chromosomal region that is frequently amplified in human cancers. Recent findings have revealed that alternative mechanisms such as epigenetic regulation also govern the expression of the encoded ZNF217 protein. Newly discovered molecular functions of ZNF217 indicate that it orchestrates complex intracellular circuits as a new key regulator of tumorigenesis. In this review, we focus on recent research on ZNF217-driven molecular functions in human cancers, revisiting major hallmarks of cancer and highlighting the downstream molecular targets and signaling pathways of ZNF217. We also discuss the exciting translational medicine investigating ZNF217 expression levels as a new powerful biomarker, and ZNF217 as a candidate target for future anti-cancer therapies.

KEYWORDS:

ZNF217; biomarker; carcinogenesis; hallmarks of cancer; oncogene

PMID:
26431164
PMCID:
PMC4747174
DOI:
10.18632/oncotarget.5893
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center